Daily Rules, Proposed Rules, and Notices of the Federal Government
Method to treat and selectively target cancer with limited toxicity.
Method to accurately diagnose cancer.
Anti-tumor therapeutic vaccines.
Anti-tumor cytoxic gene therapy constructs.
An estimated 1,444,920 new cancer cases in 2007.
600,000 cancer deaths in the U.S. in 2006.
It is estimated that market for cancer drugs would double to $50 billion a year in 2010 from $25 billion in 2006.
1. CB Buck
2. CB Buck
Available for licensing is a collagen binding protein, named aegyptin, which selectively inhibits collagen-platelet aggregation, but not platelet aggregation induced by other agonists. Collagen initiates recruitment of circulating platelets and triggers platelet activation. Collagen also plays a critical role in angiogenesis. Aegyptin blocks the interaction of collagen with its major ligands, von Willebrand factor, glycoprotein VI (GPVI), and integrin a2b1. These three ligands are of particular importance because von Willebrand factor plays a critical role in tethering platelets to collagen, GPVI is the major signaling platelet receptor, and integrin a2b1 mediates platelet adhesion and contributes to activation. Since these ligands play a critical role in the early stages of thrombus formation, aegyptin represents a potentially highly effective therapeutic that can prevent and treat patients with thrombotic disease. Alternatively, aegyptin is potentially useful in conditions where collagen plays a critical role in angiogenesis or in conditions where excessive deposition of collagen plays a pathological role (e.g. pancreatic carcinoma).
Adjuvant to "Clot busting" therapeutics.
Method to prevent and/or treat cardiovascular/thrombotic disease.
Method to treat patients undergoing invasive cardiovascular procedures (e.g. angioplasty).
Model to study collagen-dependent platelet aggregation or collagen-mediated angiogenesis.
Highly effective therapeutics can negatively modulate thrombosis in its early stages by preventing collagen interaction with three major ligands involved in thrombus/clot formation.
Aegyptin's potential use as a prototype for drug delivery as an oral therapeutic, which can reduce the need for invasive surgeries that dilate blood vessels such as stents or catheters.
Thrombolytic/antithrombotic therapies are worth billions of dollars, common therapeutics include heparin, warfarin, and plasminogen activators.
Anticancer and antiangiogenic therapies.
Cardiac disease is the number one cause of death in the U.S.
Pancreatic cancer is one of the most lethal cancers, where only 23% of patients will survive after one year of diagnosis, and 4% survive after five years of diagnosis.
An estimated 37,170 Americans will be newly diagnosed with pancreatic cancer in 2007.
An estimated 33,370 deaths from pancreatic cancer in the U.S. in 2007.
Pancreatic cancer is the fourth leading cause of cancer death in the U.S.
1. A manuscript directly related to this technology will be available as soon as it is accepted for publication.
2. E Calvo. Collagen-platelet aggregation inhibitor from mosquito salivary glands. Biacore T100 seminar series, November 2006, St. Louis, Missouri.
3. S Yoshida and H Watanabe. Robust salivary gland-specific transgene expression in
4. D Sun
This technology describes the identification of a manganese superoxide dismutase (MnSOD) polymorphism as a novel biomarker for the prognosis of doxorubicin therapeutic response in breast cancer patients, wherein a Val16Ala polymorphism of MnSOD is indicative of patient survival. More specifically, patients undergoing doxorubicin combination therapy with Val/Val, Val/Ala, and Ala/Ala genotypes had 95.2%, 79%, and 45.5% survival rates, respectively, in a case study of 70 unselected breast cancer patients. Carriers of the Ala/Ala genotype had a highly significantly poorer breast cancer-specific survival in a multivariate Cox regression analysis than carriers of the Val/Val genotype. This technology can be developed into an assay to screen for breast cancer patients who will be responsive to doxorubicin treatment. Further, as the MnSOD polymorphism is common in the population (15% to 20% of patients have the Ala/Ala genotype), it is a common risk factor for doxorubicin therapy. This technology can potentially be utilized as a screening tool applicable for all cancer types treated with doxorubicin.
A novel genetic marker that can predict breast cancer patient survival with doxorubicin treatment.
A screening test based on MnSOD Val16Ala genotype that predicts patient response to doxorubicin cancer therapy, wherein treatment can be subsequently individualized according to patient MnSOD genotype.